Citius Pharmaceuticals, Inc. (CTXR)
Develops critical care medicines including cancer immunotherapy and infection treatments.
$0.50-0.04%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-61.4%
The outlook
CTXR is trading near its 52-week low, well below both its 50- and 200-day moving averages, signaling a weak near-term trend. Analyst coverage shows an average price target roughly 7× the current price, though sentiment overall leans bearish. The stock sits at the very bottom of its yearly range with minimal upward momentum visible in recent price action.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +703% vs current price
Market cap
$13.7M
52-wk high
$2.19
52-wk low
$0.47
50-day avg
$0.58
200-day avg
$0.87
Trailing P/E
—